quinazolines has been researched along with Bilirubinemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Briley, LP; Cox, CJ; Dilthey, A; Iqbal, Z; King, KS; Li, L; McVean, G; Nelson, MR; Newcombe, PJ; Parham, LR; Shen, J; Slater, AJ; Spraggs, CF | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Adamson, PC; Blaney, SM; Conlan, MG; Dubowy, RL; Ingle, AM; Souid, AK; Sun, J | 1 |
| Alison, DL; Calvert, AH; Harland, SJ; Jackman, AL; Jones, TR; McElwain, TJ; Newell, DR; Robinson, BA; Siddik, ZH; Wiltshaw, E | 1 |
2 trial(s) available for quinazolines and Bilirubinemia
| Article | Year |
|---|---|
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Topics: Alanine Transaminase; Alleles; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Genome-Wide Association Study; HLA-DRB1 Chains; Humans; Hyperbilirubinemia; INDEL Mutation; Lapatinib; Polymorphism, Single Nucleotide; Quinazolines; Risk | 2016 |
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Benzamides; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Hyperbilirubinemia; Infant; Infusions, Intravenous; Kinesins; Maximum Tolerated Dose; Neoplasms; Neutropenia; Quinazolines; Young Adult | 2010 |
2 other study(ies) available for quinazolines and Bilirubinemia
| Article | Year |
|---|---|
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Topics: Acetylglucosaminidase; Acid Phosphatase; Alanine Transaminase; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Folic Acid; Folic Acid Antagonists; Glomerular Filtration Rate; Hematologic Diseases; Hyperbilirubinemia; Kidney Diseases; Leucyl Aminopeptidase; Neoplasms; Quinazolines; Skin Diseases; Thymidylate Synthase | 1986 |